Alan Skarbnik, MD, shares his insight on the latest updates in chronic lymphocytic leukemia presented at the 2017 ASH Annual Meeting.
The regimen of venetoclax (Venclexta) plus rituximab (Rituxan) lowered the risk of disease progression or death by 83% versus bendamustine (Treanda) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Neil E. Kay, MD, discusses the available options and sequencing challenges for patients with relapsed/refractory chronic lymphocytic leukemia, as well as next steps for advancing outcomes for this patient population.
Kerry A. Rogers, MD, discusses the promise of the obinutuzumab, ibrutinib, and venetoclax triplet as a first-line treatment for patients with chronic lymphocytic leukemia.
Matthew S. Davids, MD, discusses the key results of ibrutinib (Imbruvica) with standard frontline chemoimmunotherapy in CLL.
Ian W. Flinn, MD, discusses ongoing advances with emerging combination regimens in chronic lymphocytic leukemia.
The PI3K-delta inhibitor umbralisib (TGR-1202) induced an objective response rate of 37% in patients with relapsed/refractory lymphoma or chronic lymphocytic leukemia.
Jacqueline C. Barrientos, MD, discusses recent combination trials in CLL, and emerging agents in the pipeline.
Susan O’Brien, MD, discusses the impact that has been seen with ibrutinib following the long-term follow-up of the RESONATE studies in chronic lymphocytic leukemia.
A new drug application has been submitted to the FDA for duvelisib for a full approval for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval in relapsed/refractory follicular lymphoma.